Meanwhile, the Hyderabad-based drug major expects to launch over 15 products in the US market in 2018-19.
The company also remains optimistic for a double digit growth in the domestic market in the ongoing financial year; the PTI report suggested quoting top company official. CLICK HERE TO READ FULL REPORT
In past three months, Dr Reddy’s has underperformed the market by falling 10% as compared to 3.85% rise in the S&P BSE Sensex.
At 09:32 am; the stock was trading 3.3% higher against 0.145 gain in the benchmark index. A combined 304,023 equity shares changed hands on the counter on the BSE and NSE.